Cell Production News and Research

RSS

Animal study reveals intestinal bacteria can promote tumor growth

A team of University of California, San Diego School of Medicine researchers has discovered that common intestinal bacteria appear to promote tumor growths in genetically susceptible mice, but that tumorigenesis can be suppressed if the mice are exposed to an inhibiting protein enzyme.

10 May 2010

Mouse study may lead to new therapies for Parkinson's disease

Endometrial stem cells injected into the brains of mice with a laboratory-induced form of Parkinson's disease appeared to take over the functioning of brain cells eradicated by the disease.

7 May 2010

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it plans to initiate patient recruitment for a cancer immunotherapy study by year end. The pilot study seeks to demonstrate an improved immune function in cancer patients as a result of the Aethlon Hemopurifier removing tumor-secreted exosomes from the circulatory system.

4 May 2010

Immune system responds aggressively when looking at sick people

Just seeing someone who looks sick is enough to make your immune system work harder, according to a new study in which volunteers looked at pictures of sick people. This may help fight off pathogens, says Mark Schaller from the University of British Columbia who conducted the research. "It seems like it's probably good for the immune system to be responding especially aggressively at times when it looks like you are likely to be coming into contact with something that might make you sick."

4 May 2010

Transplanted pig cells may bring relief from insulin injections in type I diabetics

Living Cell Technologies, a New Zealand based biotechnology company that is investigating the use of living pig cells in the treatment of diabetes has now received $700,000 (US$500,000) grant from the Juvenile Diabetes Research Foundation International for further human trials.

28 Apr 2010

Phase II clinical trial to test safety and efficacy of transplanted encapsulated islets

The Juvenile Diabetes Research Foundation announced today that it is partnering with Living Cell Technologies, a New Zealand-based biotechnology company focused on developing cell based therapeutics, in a Phase II clinical trial to study the safety and effectiveness of transplanting encapsulated insulin-producing cells from pigs as a treatment for type 1 diabetes with significant hypoglycemia unawareness.

28 Apr 2010

LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, has received a grant of US$500,000 for its on-going Phase II clinical trial of DIABECELL in New Zealand from the Juvenile Diabetes Research Foundation International, a world leader in setting the agenda for diabetes research and the largest charitable funder and advocate for research in type 1 diabetes.

27 Apr 2010

Mechanisms pathogenic viruses exploit to evade immune systems of hosts

Viruses have evolved a broad range of strategies that enable them to evade the immune systems of their hosts. A team of researchers led by LMU virologist Professor J-rgen Haas has been studying a novel, recently discovered mechanism that pathogenic viruses exploit for this purpose, and their latest results could point the way to new antiviral therapies. The mechanism is based on the production of short RNA molecules, called microRNAs, by the virus.

24 Apr 2010

ImmunoCellular Therapeutics, UPENN sign research agreement

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today that the Company has entered into a sponsored research agreement and an option agreement with The University of Pennsylvania to support process development and manufacturing in a planned Phase II clinical trial of ICT-107, the Company's dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme.

22 Apr 2010

Defects in carbon nanotubes stimulate body's natural immune response: Study

Yale University engineers have found that the defects in carbon nanotubes cause T cell antigens to cluster in the blood and stimulate the body's natural immune response.

21 Apr 2010

Certain genetic mutations lead to Type 1 diabetes: The Scripps Research Institute

Scientists from The Scripps Research Institute have provided an answer to the 40-year-old mystery of how certain genetic mutations lead to Type 1 diabetes. This new molecular understanding could lead to novel therapies for Type 1 diabetes and other autoimmune diseases.

20 Apr 2010

Pivotal preclinical data of YM BioSciences' CYT387 JAK1/2 inhibitor pre-published in Blood

YM BioSciences Inc., announced the pre-publication of pivotal preclinical data for CYT387, the company's highly selective and potent JAK1/2 inhibitor, currently in a Phase I/II trial for myelofibrosis.

19 Apr 2010

Diabetic mice generate new insulin-producing cells following extreme cell destruction

Type 1 diabetes is the most common cause of diabetes in children, although it may occur at any age. Also called juvenile diabetes, this pathology usually results from autoimmune destruction of insulin-producing cells of the pancreas.

16 Apr 2010

Updates from Phase I/IIa clinical trial of DIABECELL treatment in insulin-dependent diabetics

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, today provided a penultimate update regarding the three-year follow up of its Phase I/IIa clinical trial in Russia of its DIABECELL® treatment in insulin-dependent diabetics.

7 Apr 2010

Alpha cells in pancreas can convert into insulin-producing beta cells: Study

Alpha cells in the pancreas, which do not produce insulin, can convert into insulin-producing beta cells, advancing the prospect of regenerating beta cells as a cure for type 1 diabetes. The findings come from a study at the University of Geneva, co-funded by the Juvenile Diabetes Research Foundation, that is published today in the online edition of the scientific journal Nature.

6 Apr 2010

Brain stem cells in subventricular zone characterized by transcription factor Protein Tlx

The "cradle" of new neurons in the adult brain is well known. It is what is called the subventricular zone, a tissue structure lining the lateral ventricles. This is where neural or brain stem cells reside, which are responsible for generating new neurons if needed. For many years now, the subventricular zone has been suspected to be the origin of specific malignant brain tumors called gliomas, the most deadly type of which is glioblastoma.

2 Apr 2010

New clues may help explain why some people are more susceptible to stress than others

UT Southwestern Medical Center researchers have found new clues that might help explain why some people are more susceptible to stress than others.

31 Mar 2010

LCT receives approval for New Zealand Phase II human trial of DIABECELL

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, today announced that it has received approval to advance to the next phase of its New Zealand Phase II human clinical trial with its groundbreaking DIABECELL®. The approval follows a positive assessment from the New Zealand Data Safety and Monitoring Board of the first four patients to receive its DIABACELL® implants.

30 Mar 2010

Study: Cell-based strategy for treating neurodegenerative diseases

UCSF scientists have used a novel cell-based strategy to treat motor symptoms in rats with a disease designed to mimic Parkinson's disease.

26 Mar 2010

T1D and IBD may respond to 2-way genetic switch: Study

Pediatric researchers analyzing DNA variations in type 1 diabetes and inflammatory bowel disease have found a complex interplay of genes. Some genes have opposing effects, raising the risk of one disease while protecting against the other. In other cases, a gene variant may act in the same direction, raising the risk for both diseases.

23 Mar 2010